News Lilly joins CGRP race to cure migraine Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a
News AstraZeneca and Lilly’s Alzheimer’s drug fails trial The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results.
News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News Novartis/Amgen migraine jab works in tough-to-treat patients Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.